PTX Media related, page-442

I think Edski's point in sharing the article is to keep us abreast of what is happening in the broader industry whilst we wait ever-so-patiently for a mere whisper from our management on our progress.

If you want to look on the bright side, Tiger, consider the fact that whilst ongoing endeavours and advancements are being made in the field of immunotherapy to target and combat solid tumors, they are not nearly as agnostic and simple as OmniCAR. The above article outlines a potential breakthrough in helping those patients with tumors that have a “low mutation burden”, which is wonderful, but OmniCAR has the potential to target ALL solid tumors with high and low mutation burdens including the ability to target their mutating cells. Well, that's how I read it - and am happy for others to weigh in on it with their opinions.

One thing that works in our favour is that PTX shouldn't be far off being able to take our OmniCAR technology into clinical trials, whether it be with one of own in-house CarT therapies due to finish pre-clinical testing or an external CarT therapy via a collaborative partner. We do have what appears to be a very simple and highly adaptable technology that has an advantage over other emerging technologies... and that is we are slightly ahead in terms of development. However, we don't want to lose that advantage. I can't see SYC letting that advantage slip through his fingers BUT unless the company releases news soon regarding our progress, we might see some SH slip through his fingers (much to the glee of smarties with money waiting to buy). So, as an existing holder, my message is: "FGS, Steve, get an update out!"